Pretax profits for the first quarter of 1996 rose 5% to 234 million Deutschemarks ($153.3 million) at German pharmaceutical company Schering AG. Net profits were ahead 16% to 131 million marks, and sales for the quarter rose 5% to 1.2 billion marks.
It was noted that sales were entirely driven by an increase in volumes. Schering said that in particular, the encouraging development in foreign markets has led to an over-proportional increase of 6% in foreign sales. 40 million marks of total sales were achieved by Medrad in the USA, which is consolidated since the last quarter of 1995. Slight price increases and dampening currency effects balanced each other out. The key driver for growth in therapeutic sales was Betaferon (interferon beta-1b) for the treatment of multiple sclerosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze